Drug candidates for autoimmune diseases

dc.contributor.authorSaurin, Sabrina
dc.contributor.authorMeineck, Myriam
dc.contributor.authorErkel, Gerhard
dc.contributor.authorOpatz, Till
dc.contributor.authorWeinmann-Menke, Julia
dc.contributor.authorPautz, Andrea
dc.date.accessioned2023-01-13T10:53:29Z
dc.date.available2023-01-13T10:53:29Z
dc.date.issued2022
dc.description.abstractMost of the immunosuppressive drugs used in the clinic to prevent organ rejection or to treat autoimmune disorders were originally isolated from fungi or bacteria. Therefore, in addition to plants, these are valuable sources for identification of new potent drugs. Many side effects of established drugs limit their usage and make the identification of new immunosuppressants necessary. In this review, we present a comprehensive overview of natural products with potent anti-inflammatory activities that have been tested successfully in different models of chronic inflammatory autoimmune diseases. Some of these candidates already have passed first clinical trials. The anti-inflammatory potency of these natural products was often comparable to those of established drugs, and they could be used at least in addition to standard therapy to reduce their dose to minimize unwanted side effects. A frequent mode of action is the inhibition of classical inflammatory signaling pathways, such as NF-κB, in combination with downregulation of oxidative stress. A drawback for the therapeutic use of those natural products is their moderate bioavailability, which can be optimized by chemical modifications and, in addition, further safety studies are necessary. Altogether, very interesting candidate compounds exist which have the potential to serve as starting points for the development of new immunosuppressive drugs.en_GB
dc.description.sponsorshipGefördert durch die Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 491381577
dc.identifier.doihttp://doi.org/10.25358/openscience-8566
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/8582
dc.language.isoeng
dc.rightsCC-BY-4.0
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleDrug candidates for autoimmune diseasesen_GB
dc.typeZeitschriftenaufsatzde_DE
jgu.apc.membershipMDPI (MDPI)
jgu.apc.netprice1623,08
jgu.apc.price1736,70
jgu.apc.taxrate7
jgu.dfg.year2022
jgu.journal.issue5
jgu.journal.titlePharmaceuticals
jgu.journal.volume15
jgu.nationalcurrency.eur1623,08
jgu.organisation.departmentFB 04 Medizinde_DE
jgu.organisation.nameJohannes Gutenberg-Universität Mainzde_DE
jgu.organisation.number2700
jgu.organisation.placeMainz
jgu.organisation.rorhttps://ror.org/023b0x485
jgu.pages.alternative503
jgu.publisher.doi10.3390/ph15050503
jgu.publisher.issn1424-8247
jgu.publisher.nameMDPI
jgu.publisher.placeBasel
jgu.publisher.year2022
jgu.rights.accessrightsopenAccessen_GB
jgu.subject.ddccode610
jgu.subject.dfgLebenswissenschaftende_DE
jgu.type.contenttypeScientific articleen_GB
jgu.type.dinitypeArticleen_GB
jgu.type.resourceTexten_GB
jgu.type.versionPublished versionen_GB

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
drug_candidates_for_autoimmun-20230112132020289.pdf
Size:
3.6 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
3.57 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections